CLINICAL, CYTOGENETIC AND MOLECULAR CHARACTERIZATION OF BRAZILIAN COHORT PATIENTS WITH PRIMERY MYELOFIBROSIS AND MYELOFIBROSIS POST-POLYCYTTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA
Introduction: Myelofibrosis (MF) is the most severe myeloproliferative neoplasia (MPN), with a very variable survival, which can be beyond 20 years to less than two years. The only curative treatment is allogeneic bone marrow transplantation (ABMT), but this is restricted to patients of less advance...
Main Authors: | RS Tavares, NCD Clementino, MRM Conchon, KBB Pagnano, SA Santana, ACKVD Nascimento, VAM Funke, RT Centrone, FS Seguro, JAP Bortolini, DA Silveira, I Bendit |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-10-01
|
Series: | Hematology, Transfusion and Cell Therapy |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137921003667 |
Similar Items
-
The importance of cytogenetics in polycythemia vera, primary myelofibrosis and essential thrombocythemia
by: Monika Conchon
Published: (2011-12-01) -
Analysis of demographic and clinical characteristics of primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis patients
by: P. Akyol, et al.
Published: (2020-10-01) -
P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA
by: Z. Xu, et al.
Published: (2022-06-01) -
Case report: Effectiveness of low-dose methotrexate monotherapy in post-essential thrombocythemia myelofibrosis
by: Sebastian Francis, et al.
Published: (2024-04-01) -
PB2211: DIFFERENCES IN POST-POLYCYTHEMIA VERA AND POST–ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS VS PRIMARY MYELOFIBROSIS IN FIBROTIC STAGE: A RETROSPECTIVE, REAL-WORLD STUDY CONDUCTED IN CHINA
by: Shengjie Wang, et al.
Published: (2023-08-01)